Latest Articles
-
After MRK’s 6.8% Climb in a Day, INVA Looks Like the Stronger Long-Term Play
Innoviva (INVA) offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Merck (MRK), suggesting you may be better off investing in INVA INVA’s quarterly revenue growth was 0.4%, vs. MRK&#...
-
S&P 500 Movers | Winners: PFE, MRK, DHR | Losers: ALB, MGM, COF
On Tuesday, September 30, a market-wide surge lifted the S&P 500 rising 0.41%, the Dow 30 rising 0.18%, and the Nasdaq 100 rising 0.28%. Gains were broad-based, though not every stock joined the rally. List of S&P 500 Winners ...
-
Better Bet Than Elanco Animal Health Stock: Pay Less To Get More From LLY, MRK
LLY, MRK are ELAN’s peers in Pharmaceuticals industry that have: 1) Lower valuation (P/OpInc) compared to ELAN 2) But higher revenue and operating income growth This disconnect between valuation and performance could mean that you are bet...
-
Ten-Year Tally: MRK Hands Back $89 Bil to Shareholders
In the last decade, Merck (MRK) has returned a notable $89 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the market’s bi...
-
MRK Stock Up 6.1% after 6-Day Win Streak
Merck (MRK) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 6.1% return. The company has gained about $13 Bil in value over the last 6 days, with its current market capitalization a...
-
MRK Stock Up 5.2% after 5-Day Win Streak
Merck (MRK) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 5.2% return. The company has gained about $11 Bil in value over the last 5 days, with its current market capitalization a...
-
MRK Testing Price Floor: Time to Load Up?
Merck (MRK) should be on your watchlist. Here is why – it is currently trading in the support zone ($76.28 – $84.31), levels from which it has bounced meaningfully before. In the last 10 years, the stock received buying interest at th...
-
Will Merck Stock Rise On Its Upcoming Earnings?
Merck (NYSE:MRK) is scheduled to announce its earnings on Tuesday, July 29, 2025. Historically, MRK stock has shown a tendency for negative one-day returns following earnings announcements. Over the past five years, the stock experienced a declin...
-
Better Bet Than AbbVie Stock: Pay Less To Get More From Industry Peers
GILD, MRK are ABBV’s peers in Biotechnology industry that have: 1) Lower valuation (P/EBIT) compared to ABBV 2) But higher revenue and operating income growth This disconnect between valuation and performance could mean that you are bette...
-
Merck’s Latest Move: Why the Verona Deal Still Leaves Questions
Merck’s latest acquisition announcement sends a clear message about its urgency to address the looming Keytruda patent cliff. The pharmaceutical giant has agreed to purchase COPD drugmaker Verona Pharma for $10 billion, adding another poten...
-
Merck’s Upside Potential: Beyond The Keytruda Cliff
While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month, we discussed how Keytruda is a ticking time bomb ...
-
Merck’s Keytruda Dependency: A Growth Story With An Expiration Date
Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely driven by Keytruda, a blockbuster oncology treatme...
-
What’s Next For Merck After A Q1 Beat?
Merck (NYSE: MRK) recently released its first-quarter results, surpassing Wall Street’s expectations for both revenue and earnings. The company reported revenue of $15.53 billion and adjusted earnings per share of $2.22, exceeding consen...
-
How Will Merck Stock React To Its Upcoming Earnings?
Merck (NYSE:MRK) is scheduled to release its earnings report on Thursday, April 24, 2025. Historical data suggests a potential negative reaction in MRK stock following the announcement. Over the past five years, the stock has experienced a nega...
-
Market Turmoil? Look At Healthcare Dividend Stocks With 3%+ Yields
The S&P 500’s 9% decline in 2025, triggered by President Trump’s tariffs and heightened trade tensions with China, has created a challenging investment landscape. Despite this downturn, select healthcare stocks show resilience by ...
